At the National Society of Genetic Counselors meeting in San Diego, CA today, GenPath Women’s Health, one of the leading Women’s Health laboratories in the United States in collaboration with GeneDX, one of the leading genetic laboratories in the world specializing in rare genetic disorders, and both divisions of BioReference Laboratories, Inc. (NASDAQ - BRLI), announced a groundbreaking genetic screening test that will identify more than 550 mutations in over 160 diseases. The Pan-Ethnic Carrier Screen is a simple blood test and will be the most comprehensive genetic screening test offered by any laboratory; it will allow individuals from at-risk groups, as well as individuals who are unsure if they are at-risk, to determine the likelihood of dangerous genetic mutations being passed on to their children. Offered primarily through GenPath Women’s Health which has contracts with most national insurance plans, the test will be offered by the patient’s physician, obstetrician or genetic counselor during the first trimester or prior to conception.

“This test is another illustration of our world-class leadership and innovation in genomic testing. It is more testing for more genes or mutations but, more than that, it is the strength of the physicians and scientists at BioReference who have developed and stand behind this test that differentiates us in the market.” said Marc D. Grodman, MD, President and CEO of Bio-Reference Laboratories. “Because our test can identify such a broad and diverse range of genetic mutations and diseases, the value we will provide to women and their families is undeniable. These parents will be able to go through genetic counseling armed with accurate information about potential risks to their children.”

In addition to the wide scope of genetic mutations and diseases that can be identified through the test, physicians and patients will receive a detailed, easy to read and understand summary of the screening on a clinical report. The report will illustrate tracking for any mutations on a circular graph. The two graphs – one for a man and one for a woman – are then overlaid. If none of the mutations line up, meaning they are not shared by both parties, there is little danger. Where they do line up, meaning they do share a mutation, the couple can then be counseled as to the risks and options.

The test will be available from GenPath in January 2012.

About Bio-Reference Laboratories, Inc.

BRLI is the fourth largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing laboratory servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology, women's health and correctional health care. BRLI operates as a national oncology laboratory as GenPath. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI's innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women's Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.

Copyright Business Wire 2010